Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 06, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
August 10, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

– Patients with MTAP-deleted solid tumors being actively enrolled in ongoing Phase 1/2 trial of TNG908, an MTA-cooperative PRMT5 inhibitor – – Received Orphan Drug Designation in US for the treatment...
August 02, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
June 27, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
June 08, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
May 11, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

– Phase 1/2 trial of TNG908, a synthetic lethal PRMT5 inhibitor, for the treatment of MTAP-deleted solid tumors open for enrollment – – Declared TNG462 as a development candidate - a...
May 09, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in the Guggenheim Synthetic Lethality Day 2022

CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
March 28, 2022 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

- TNG908 receives Fast Track designation, expects Phase 1/2 trial to start in 2Q 2022 - - Pipeline programs progressing throughout 2022 - - Strong cash position of $485 million expected to...
March 08, 2022 16:57 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
March 03, 2022 09:41 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies Congress

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...